RELIABILITY OF DSMIII-R & ICD-10 SUBSTANCE USE DISORDERS

DSMIII-R 的可靠性

• 批准号: 3212026
• 负责人: Linda B. Cottler
• 金额: $ 10.32万
• 依托单位: WASHINGTON UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1988
• 资助国家: 美国
• 起止时间: 1988-09-30 至 1991-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/3212026
• 关键词: Cannabis; adult human (21+); alcoholic beverage consumption; amphetamines; behavior test; cocaine; data collection methodology /evaluation; diagnosis quality /standard; drug abuse; drug addiction; drug adverse effect; human subject; interview; mental disorder diagnosis; mental disorders; opiate alkaloid; phencyclidine; psychopharmacologic agent; psychotomimetic drug; sedative /hypnotic; statistics /biometry; tranquilizer

The proposed study will determine the interrater reliability of and diagnostic agreements between DSM-III-R and ICD-10 psychoactive substance use disorders through personal interviews using the WHO/ADAMHA Composite International Diagnostic Interview Substance Abuse Module (CIDI-AM). A pilot study conducted by the applicant found good to excellent agreement for most DSM-III-R substance use disorders. In the proposed study a sample of 125 clinical and community substance abusers will be interviewed with a test re-test design of two interviews per subject. After the second interview the interviews to determine the reason for discrepant information. The analysis will evaluate interrater reliability of DSM-III-R, and ICD-10 psychoactive substance disorders. The two systems will be compared with respect to the dependence syndrome and hazardous use and abuse. Key indicators of dependence criteria such as loss of control, craving, salience and narrowing of repertoire will be examined. Kappa statistics and 95% confidence intervals will be calculated for all comparisons. It is expected that the findings from this study will influence future decisions about the diagnostic criteria for substance abuse and dependence. * psychoactive substances include alcohol, amphetamine, cannabis, cocaine, hallucinogens, inhalants, opioids, PCP, and sedatives, hypnotics,anxiolytics.

拟议的研究将确定评价者间的可靠性和 DSM-III-R与ICD-10精神活性药物的诊断一致性 物质使用障碍通过个人访谈使用 WHO/ADAMHA复合国际诊断面谈物质 滥用模块（CIDI-AM）。 申请人进行的试点研究 发现大多数DSM-III-R物质使用的一致性良好至极好 紊乱 在拟议的研究中， 社区药物滥用者将接受面谈， 每个主题设计两次访谈。 第二次面试后 通过访谈确定信息不一致的原因。 该分析将评估DSM-III-R的评定者间信度， ICD-10精神活性物质障碍。 这两个系统将 与依赖综合症和危险使用相比 和虐待 依赖性标准的关键指标，如丧失 控制，渴望，突出和缩小剧目将是 考察 Kappa统计量和95%置信区间将 计算所有比较。 预计调查结果 这项研究将影响未来的决定， 药物滥用和依赖的诊断标准。 * 精神活性物质包括酒精，安非他明，大麻， 可卡因、致幻剂、吸入剂、阿片类药物、PCP和镇静剂， 催眠药抗焦虑药